强化心血管病急救培训和继续教育,改善中国的心血管疾病和心脏骤停救治效果

2018-10-13 MedSci MedSci原创

北京--星期五,10月12日--美国心脏协会(AHA),作为美国历史最悠久,规模最大的致力于在全球挽救心脏病人和卒中患者生命的志愿组织,与中国医师协会(CDMA)签署谅解备忘录,进一步促进双方的沟通和协作,协调资源,在中国挽救更多心脏病人和卒中患者的生命。据世界卫生组织(WHO)估计,中国约有2.3亿人罹患心血管疾病 ,即每五个成年人中就有一个患有心血管疾病 。尽管采取了各种努力减少病患数量并改善



北京--星期五,10月12日--美国心脏协会(AHA),作为美国历史最悠久,规模最大的致力于在全球挽救心脏病人和卒中患者生命的志愿组织,与中国医师协会(CDMA)签署谅解备忘录,进一步促进双方的沟通和协作,协调资源,在中国挽救更多心脏病人和卒中患者的生命。

据世界卫生组织(WHO)估计,中国约有2.3亿人罹患血管疾病 ,即每五个成年人中就有一个患有血管疾病 。尽管采取了各种努力减少病患数量并改善心脏健康,心血管疾病发病率仍呈上升趋势。

通过拓展合作,将促进双方的科学交流,改进中国健康医疗人员进行心血管病急救的质量,必将进一步提升心脏骤停的处理效果。中国医师协会拥有450多万名成员,其中有近6万人是心脏病专家。

"美国心脏协会的全球事业几乎总是基于战略协作,包括与政府、医师群体、科研人员和像中国医师协会这样的国内组织",美国心脏协会主席艾弗·本杰明指出,"正是本着协作精神,今天两个组织走到一起,必将为双方的成功合作掀开新的篇章"。

本次谅解备忘录的签署表明双方有意愿进一步规范中国的心脏病医师培训,展开科研,制定治疗指南,为病人实现更好的治疗效果。

美国心脏协会和中国医师协会将联合培训百分之五十的从事重症监护(CCU和ICU)工作的心脏病专家和医师,以及在急诊科工作的医师。项目为期五年。

关于美国心脏协会

美国心脏协会致力于挽救心脏病和卒中病人的生命--全球两大主要致死病因。我们与数百万的志愿者携手资助创新研究,推动更有力的公共健康政策,提供挽救生命的工具和信息,展开疾病防治。协会总部位于达拉斯,是美国历史最为悠久、规模最大的专注于心脏病和卒中的志愿者组织。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1941673, encodeId=a42419416e33a, content=<a href='/topic/show?id=e970e89890c' target=_blank style='color:#2F92EE;'>#继续教育#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78989, encryptionId=e970e89890c, topicName=继续教育)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=570c172, createdName=tigerlr98, createdTime=Mon Nov 12 16:59:00 CST 2018, time=2018-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1644707, encodeId=3a791644e07e4, content=<a href='/topic/show?id=e3eb89e17fb' target=_blank style='color:#2F92EE;'>#血管病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89717, encryptionId=e3eb89e17fb, topicName=血管病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=64bb23195917, createdName=Luyuxie_17, createdTime=Fri Aug 23 04:59:00 CST 2019, time=2019-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1498483, encodeId=720b1498483e9, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Mon Oct 15 01:59:00 CST 2018, time=2018-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1046644, encodeId=22cb104664400, content=疗效只是效果的众多方面之一,还要看对患者的获益,包括生活质量等因素共同决定效果的, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CHANGE, createdTime=Sat Oct 13 13:59:00 CST 2018, time=2018-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=349166, encodeId=401a34916637, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/iaAVWEsIJUkA1ITy3uL0lhHUhyaJibWgFtH4KbJuaLbY2WUK33jgCFyoZ8Eqx7eE7hCuZhytc1C5GRrfjVXN8lYg/0, createdBy=fcb82149579, createdName=183****7028, createdTime=Sat Oct 13 13:22:00 CST 2018, time=2018-10-13, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1941673, encodeId=a42419416e33a, content=<a href='/topic/show?id=e970e89890c' target=_blank style='color:#2F92EE;'>#继续教育#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78989, encryptionId=e970e89890c, topicName=继续教育)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=570c172, createdName=tigerlr98, createdTime=Mon Nov 12 16:59:00 CST 2018, time=2018-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1644707, encodeId=3a791644e07e4, content=<a href='/topic/show?id=e3eb89e17fb' target=_blank style='color:#2F92EE;'>#血管病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89717, encryptionId=e3eb89e17fb, topicName=血管病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=64bb23195917, createdName=Luyuxie_17, createdTime=Fri Aug 23 04:59:00 CST 2019, time=2019-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1498483, encodeId=720b1498483e9, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Mon Oct 15 01:59:00 CST 2018, time=2018-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1046644, encodeId=22cb104664400, content=疗效只是效果的众多方面之一,还要看对患者的获益,包括生活质量等因素共同决定效果的, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CHANGE, createdTime=Sat Oct 13 13:59:00 CST 2018, time=2018-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=349166, encodeId=401a34916637, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/iaAVWEsIJUkA1ITy3uL0lhHUhyaJibWgFtH4KbJuaLbY2WUK33jgCFyoZ8Eqx7eE7hCuZhytc1C5GRrfjVXN8lYg/0, createdBy=fcb82149579, createdName=183****7028, createdTime=Sat Oct 13 13:22:00 CST 2018, time=2018-10-13, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1941673, encodeId=a42419416e33a, content=<a href='/topic/show?id=e970e89890c' target=_blank style='color:#2F92EE;'>#继续教育#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78989, encryptionId=e970e89890c, topicName=继续教育)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=570c172, createdName=tigerlr98, createdTime=Mon Nov 12 16:59:00 CST 2018, time=2018-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1644707, encodeId=3a791644e07e4, content=<a href='/topic/show?id=e3eb89e17fb' target=_blank style='color:#2F92EE;'>#血管病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89717, encryptionId=e3eb89e17fb, topicName=血管病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=64bb23195917, createdName=Luyuxie_17, createdTime=Fri Aug 23 04:59:00 CST 2019, time=2019-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1498483, encodeId=720b1498483e9, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Mon Oct 15 01:59:00 CST 2018, time=2018-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1046644, encodeId=22cb104664400, content=疗效只是效果的众多方面之一,还要看对患者的获益,包括生活质量等因素共同决定效果的, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CHANGE, createdTime=Sat Oct 13 13:59:00 CST 2018, time=2018-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=349166, encodeId=401a34916637, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/iaAVWEsIJUkA1ITy3uL0lhHUhyaJibWgFtH4KbJuaLbY2WUK33jgCFyoZ8Eqx7eE7hCuZhytc1C5GRrfjVXN8lYg/0, createdBy=fcb82149579, createdName=183****7028, createdTime=Sat Oct 13 13:22:00 CST 2018, time=2018-10-13, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1941673, encodeId=a42419416e33a, content=<a href='/topic/show?id=e970e89890c' target=_blank style='color:#2F92EE;'>#继续教育#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78989, encryptionId=e970e89890c, topicName=继续教育)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=570c172, createdName=tigerlr98, createdTime=Mon Nov 12 16:59:00 CST 2018, time=2018-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1644707, encodeId=3a791644e07e4, content=<a href='/topic/show?id=e3eb89e17fb' target=_blank style='color:#2F92EE;'>#血管病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89717, encryptionId=e3eb89e17fb, topicName=血管病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=64bb23195917, createdName=Luyuxie_17, createdTime=Fri Aug 23 04:59:00 CST 2019, time=2019-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1498483, encodeId=720b1498483e9, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Mon Oct 15 01:59:00 CST 2018, time=2018-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1046644, encodeId=22cb104664400, content=疗效只是效果的众多方面之一,还要看对患者的获益,包括生活质量等因素共同决定效果的, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CHANGE, createdTime=Sat Oct 13 13:59:00 CST 2018, time=2018-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=349166, encodeId=401a34916637, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/iaAVWEsIJUkA1ITy3uL0lhHUhyaJibWgFtH4KbJuaLbY2WUK33jgCFyoZ8Eqx7eE7hCuZhytc1C5GRrfjVXN8lYg/0, createdBy=fcb82149579, createdName=183****7028, createdTime=Sat Oct 13 13:22:00 CST 2018, time=2018-10-13, status=1, ipAttribution=)]
    2018-10-13 CHANGE

    疗效只是效果的众多方面之一,还要看对患者的获益,包括生活质量等因素共同决定效果的

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1941673, encodeId=a42419416e33a, content=<a href='/topic/show?id=e970e89890c' target=_blank style='color:#2F92EE;'>#继续教育#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78989, encryptionId=e970e89890c, topicName=继续教育)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=570c172, createdName=tigerlr98, createdTime=Mon Nov 12 16:59:00 CST 2018, time=2018-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1644707, encodeId=3a791644e07e4, content=<a href='/topic/show?id=e3eb89e17fb' target=_blank style='color:#2F92EE;'>#血管病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89717, encryptionId=e3eb89e17fb, topicName=血管病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=64bb23195917, createdName=Luyuxie_17, createdTime=Fri Aug 23 04:59:00 CST 2019, time=2019-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1498483, encodeId=720b1498483e9, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Mon Oct 15 01:59:00 CST 2018, time=2018-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1046644, encodeId=22cb104664400, content=疗效只是效果的众多方面之一,还要看对患者的获益,包括生活质量等因素共同决定效果的, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CHANGE, createdTime=Sat Oct 13 13:59:00 CST 2018, time=2018-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=349166, encodeId=401a34916637, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/iaAVWEsIJUkA1ITy3uL0lhHUhyaJibWgFtH4KbJuaLbY2WUK33jgCFyoZ8Eqx7eE7hCuZhytc1C5GRrfjVXN8lYg/0, createdBy=fcb82149579, createdName=183****7028, createdTime=Sat Oct 13 13:22:00 CST 2018, time=2018-10-13, status=1, ipAttribution=)]
    2018-10-13 183****7028

    学习

    0

相关资讯

JACC:经皮室间隔消融术治疗肥厚型梗阻性心肌病安全有效

对于由肥厚型梗阻性心肌病(HOCM)致残的患者,经皮心肌内间隔射频消融术(PIMSRA)可能是一个侵入性低的治疗选择。本研究的目的旨在评估PIMSRA对缓解HOCM患者的左室流出道压差的安全性和有效性。本研究纳入了15例HOCM患者,并在术后6个月的随访期间对其心电图、影像学和生化检测进行评估。经过6个月时间的随访,患者的左室流出道峰值压差明显降低(静息压差88.00 [66.00] mm Hg

JACC:冠脉剪切应力可以预测冠心病患者的心梗风险

冠脉损伤伴低节段性流量储备(FFR)与更高的血管再生率相关,高壁剪切应力(WSS)与斑块易损性增加有关。本研究的目的旨在评估稳定性冠心病(CAD)患者的WSS与心梗发生的相关性。在FAME II临床研究的FFR ≤0.80的441例患者中,34例(8%)患者在3年内发生了心梗。29例发生血管相关性心梗且有适合三维重建的血管造影照片的患者与29例无心梗的对照进行了匹配分析。这58例患者的平均年龄为6

Circulation:老年痛风患者的心血管风险:非布司他vs别嘌醇

老年人是心血管疾病高危人群。既往研究表明,痛风增加心血管疾病的风险。2018年6月,发表在《Circulation》的一项基于人群的队列研究调查了非布司他vs别嘌醇对于老年痛风患者的心血管风险。

JACC:糖尿病患者强化降压 心血管风险会降低?

2018年9月,发表于《J Am Coll Cardiol》上的一项研究,考察了对糖尿病成人患者普遍强化血压(BP)治疗的效果。

JACC:冠心病的遗传风险评分体系

冠心病(CAD)是一类多基因的疾病,然而尚缺乏一个能帮助预测CAD预后的遗传风险评分体系。本研究的目的旨在构建一个CAD的遗传风险评分体系,以作为冠心病初级预防的工具。本研究结合全基因组和靶向测序数据库的数据,构建了一个包含170万个遗传变异的CAD遗传风险评估体系(metaGRS),并利用这个体系对UK生物库中的22242例CAD患者和460387例对照进行测试评估。分析结果发现,metaGRS

Circulation:慢性肾病并不是卡格列净的禁忌症!

卡格列净是通过批准的、可用于降低2型糖尿病血糖的药物,对心血管和肾脏具有保护作用。卡格列净对其尚未批准应用的慢性肾病患者(包括估算的肾小球滤过率[eGFR]在30-45mL/min/1.73m2的)是否有益?Brendon L. Neuen等人对此展开研究。CANVAS项目将10 142位eGFR>30mL/min/1.73m2的2型糖尿病患者随机分至卡格列净或安慰剂组。主要结点是心血管原因